RxDoctor Payments Data

Anne Littell, DO

Family Medicine · Kissimmee, FLNPI 1942707328

Payments from drug & device makers

$3,274in general payments, 2019–2025

Across 169 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$417
  • GSK$320
  • Boehringer Ingelheim$290
  • Lilly USA, LLC$233
  • Daiichi Sankyo Inc.$177
  • plus $815 from 12 others

What the payments were for

  • Food & beverage$3,274100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,274 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$155,263
Medicare patients
366
Services billed
1,891

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin95$105,626
EliquisApixaban66$73,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$54,676
TrulicityDulaglutide23$31,071
OzempicSemaglutide22$30,543
JanuviaSitagliptin Phosphate32$29,527
FarxigaDapagliflozin Propanediol18$23,144
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$14,680
XareltoRivaroxaban20$14,245
SynthroidLevothyroxine Sodium51$4,165
Duloxetine Hcl82$2,243
Albuterol Sulfate HfaAlbuterol Sulfate57$1,841
Omeprazole94$1,659
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,613
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen63$1,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$290$105,62695 claims
PfizerEliquis$113$73,48666 claims
GSKTrelegy Ellipta$320$54,67658 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,021$37,82429 claims
Lilly USA, LLCTrulicity$233$31,07123 claims
Novo NordiskOzempic$417$30,54322 claims
AbbVieSynthroid$124$4,16551 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,405179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →